| Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours EFPM Schoenmakers, S Wanschura, R Mols, J Bullerdiek, ... Nature genetics 10 (4), 436-444, 1995 | 661 | 1995 |
| Histamine receptor H1–mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome MM Wouters, D Balemans, S Van Wanrooy, J Dooley, V Cibert-Goton, ... Gastroenterology 150 (4), 875-887. e9, 2016 | 391 | 2016 |
| Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories R Hayeshi, C Hilgendorf, P Artursson, P Augustijns, B Brodin, ... European Journal of Pharmaceutical Sciences 35 (5), 383-396, 2008 | 303 | 2008 |
| Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica R Mellaerts, R Mols, JAG Jammaer, CA Aerts, P Annaert, ... European Journal of Pharmaceutics and Biopharmaceutics 69 (1), 223-230, 2008 | 296 | 2008 |
| Characterization of human duodenal fluids in fasted and fed state conditions D Riethorst, R Mols, G Duchateau, J Tack, J Brouwers, P Augustijns Journal of pharmaceutical sciences 105 (2), 673-681, 2016 | 256 | 2016 |
| LPP, the Preferred Fusion Partner Gene ofHMGICin Lipomas, Is a Novel Member of the LIM Protein Gene Family MMR Petit, R Mols, EFPM Schoenmakers, N Mandahl, WJM Van de Ven Genomics 36 (1), 118-129, 1996 | 253 | 1996 |
| Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica M Van Speybroeck, R Mellaerts, R Mols, T Do Thi, JA Martens, ... European Journal of Pharmaceutical Sciences 41 (5), 623-630, 2010 | 244 | 2010 |
| Metabolism of stevioside in pigs and intestinal absorption characteristics of stevioside, rebaudioside A and steviol JMC Geuns, P Augustijns, R Mols, JG Buyse, B Driessen Food and Chemical Toxicology 41 (11), 1599-1607, 2003 | 183 | 2003 |
| Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole M Van Speybroeck, R Mols, R Mellaerts, T Do Thi, JA Martens, ... European Journal of Pharmaceutics and Biopharmaceutics 75 (3), 354-365, 2010 | 141 | 2010 |
| The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model R Abdelnabi, CS Foo, SJF Kaptein, X Zhang, TND Do, L Langendries, ... EBioMedicine 72, 2021 | 140 | 2021 |
| The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern R Abdelnabi, CS Foo, D Jochmans, L Vangeel, S De Jonghe, ... Nature Communications 13 (1), 719, 2022 | 126 | 2022 |
| Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport R Mellaerts, R Mols, P Kayaert, P Annaert, J Van Humbeeck, ... International journal of pharmaceutics 357 (1-2), 169-179, 2008 | 106 | 2008 |
| Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites R Mallants, K Van Oosterwyck, L Van Vaeck, R Mols, E De Clercq, ... Xenobiotica 35 (10-11), 1055-1066, 2005 | 98 | 2005 |
| The angiotensin converting enzyme inhibitory tripeptides Ile-Pro-Pro and Val-Pro-Pro show increasing permeabilities with increasing physiological relevance of absorption models M Foltz, A Cerstiaens, A van Meensel, R Mols, PC van der Pijl, ... Peptides 29 (8), 1312-1320, 2008 | 97 | 2008 |
| Proton pump inhibitors reduce duodenal eosinophilia, mast cells, and permeability in patients with functional dyspepsia L Wauters, M Ceulemans, D Frings, M Lambaerts, A Accarie, J Toth, ... Gastroenterology 160 (5), 1521-1531. e9, 2021 | 94 | 2021 |
| Physical mapping of chromosome 12q breakpoints in lipoma, pleomorphic salivary gland adenoma, uterine leiomyoma, and myxoid liposarcoma EFPM Schoenmakers, PFJ Kools, R Mols, B Kazmierczak, S Bartnitzke, ... Genomics 20 (2), 210-222, 1994 | 74 | 1994 |
| Itraconazole/TPGS/Aerosil® 200 solid dispersions: characterization, physical stability and in vivo performance B Van Eerdenbrugh, M Van Speybroeck, R Mols, K Houthoofd, ... European journal of pharmaceutical sciences 38 (3), 270-278, 2009 | 70 | 2009 |
| The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate TT Do, M Van Speybroeck, R Mols, P Annaert, J Martens, ... International journal of pharmaceutics 414 (1-2), 118-124, 2011 | 65 | 2011 |
| HPLC with programmed wavelength fluorescence detection for the simultaneous determination of marker compounds of integrity and P-gp functionality in the Caco-2 intestinal … P Augustijns, R Mols Journal of pharmaceutical and biomedical analysis 34 (5), 971-978, 2004 | 59 | 2004 |
| Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine N Holmstock, T De Bruyn, J Bevernage, P Annaert, R Mols, J Tack, ... European Journal of Pharmaceutical Sciences 49 (1), 27-32, 2013 | 54 | 2013 |
